Lakefront Biotherapeutics (LKFT) Capital Expenditures (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has 13 years of Capital Expenditures data on file, last reported at -$144001.7 in Q1 2026.

• Capital Expenditures for Q1 2026 came in at -$144001.7, up 97.31% year-over-year; the trailing twelve-month figure through Mar 2026 was $21.9 million (up 33.66% YoY), and the FY2025 annual result was $16.0 million, down 10.72% from the prior year.
• Capital Expenditures retreated to -$144001.7 in Q1 2026 per LKFT's latest filing, from $30.0 million in the prior quarter.
• Over five years, Capital Expenditures peaked at $48.2 million in Q4 2022 and troughed at -$10.3 million in Q1 2022.
• A 5-year average of $7.7 million and a median of -$3.6 million in 2024 frame the typical range for Capital Expenditures.
• The sharpest annual moves came in 2023 and 2026: Capital Expenditures plunged 33.46% in 2023, then surged 97.31% in 2026.
• A 5-year view of Capital Expenditures shows it stood at $48.2 million in 2022, then sank by 33.46% to $32.0 million in 2023, then dropped by 6.55% to $29.9 million in 2024, then increased by 0.32% to $30.0 million in 2025, then tumbled by 100.48% to -$144001.7 in 2026.
• Business Quant data shows LKFT's Capital Expenditures at -$144001.7 in Q1 2026, $30.0 million in Q4 2025, and -$3.3 million in Q3 2025.